Abstract
Class II major histocompatibility complex (MHC II) is normally silenced in plasma/multiple myeloma (MM) cells at the transcriptional level through downregulation of class II transactivator (CIITA), allowing MM cells to escape from immunological responses. Here we demonstrate that a retinoic acid receptor-alpha/beta-selective retinoid Am80 (tamibarotene) could induce the expression of functional MHC II molecules in human MM cell lines. Am80 upregulated expression of the interferon regulatory factor-1 gene, followed by enhancement of CIITA expression. This is the first report demonstrating that retinoid can induce the expression of MHC II in terminally-differentiated plasma/MM cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anticarcinogenic Agents / pharmacology
-
Benzoates / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation
-
DNA, Complementary / metabolism
-
Gene Expression Profiling
-
Gene Expression Regulation, Neoplastic*
-
Genes, MHC Class II / genetics*
-
Histocompatibility Antigens Class II / biosynthesis*
-
Humans
-
Jurkat Cells
-
Multiple Myeloma / immunology*
-
Multiple Myeloma / metabolism
-
NF-kappa B / metabolism
-
Oligonucleotide Array Sequence Analysis
-
Retinoids / metabolism*
-
Tetrahydronaphthalenes / pharmacology*
Substances
-
Anticarcinogenic Agents
-
Benzoates
-
DNA, Complementary
-
Histocompatibility Antigens Class II
-
NF-kappa B
-
Retinoids
-
Tetrahydronaphthalenes
-
tamibarotene